NVCT Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology...

Stats
Today's Volume	20 996.00
Average Volume	92 768.00
Market Cap	115.50M
EPS	$0 ( 2024-03-05 )
Next earnings date	( $-0.400 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.55
ATR14	$0.0220 (0.34%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Bentsur Ron	Buy	5 000	Common Stock
2024-01-03	Poradosu Enrique	Buy	130 000	Common Stock
2024-01-03	Shemesh Shay	Buy	130 000	Common Stock
2023-10-10	Bentsur Ron	Buy	640	Common Stock
2023-10-09	Bentsur Ron	Buy	830	Common Stock

INSIDER POWER
100.00
Last 100 transactions
Buy: 1 056 063 \| Sell: 0

Volume Correlation

Long: 0.00 (neutral)

Short: 0.22 (neutral)

Signal:(49.679) Neutral

Nuvectis Pharma, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nuvectis Pharma, Inc. Correlation - Currency/Commodity

-0.02
( neutral )

0.00
( neutral )

0.01
( neutral )

-0.26
( neutral )

0.15
( neutral )

Nuvectis Pharma, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-22.90M (0.00 %)
EPS:	$-1.430

FY	2023
Revenue:	$0
Gross Profit:	$-22.90M (0.00 %)
EPS:	$-1.430

FY	2022
Revenue:	$149 000
Gross Profit:	$-19.09M (-12 808.72 %)
EPS:	$-1.480

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.091

Financial Reports:

No articles found.

Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.